natgillin/translations-raw huggingface dataset:
The magnitude of exposure increases due to interactions does not raise any safety concerns given the safety experience of treatment with Onbrez Breezhaler in clinical studies of up to one year at doses up to twice the maximum recommended therapeutic dose. 
Koostoimetest tingitud ekspositsiooni suurenemise ulatus ei tõstata ohutusalaseid küsimusi, kuna Onbrez Breezhaler'i kasutamine kliinilistes uuringutes kuni ühe aasta vältel maksimaalsest soovitatavast terapeutilisest annusest kuni kaks korda suuremates annustes oli ohutu.
Driving and using machines It is unlikely that Onbrez Breezhaler will affect your ability to drive and use machines. 
Autojuhtimine ja masinatega töötamine On ebatõenäoline, et Onbrez Breezhaler võiks mõjutada autojuhtimise ja masinatega töötamise võimet.
What Onbrez Breezhaler looks like and content of the pack In this pack, you will find an inhaler, together with capsules in blisters. 
Kuidas Onbrez Breezhaler välja näeb ja pakendi sisu Sellest pakendist leiate inhalaatori ja kapslid blistrites.
As demonstrated in 605 patients with COPD in a 26-week, double-blind, placebo-controlled Phase III study, there was no clinically relevant difference in the development of arrhythmic events monitored over 24 hours, at baseline and up to 3 times during the 26-week treatment period, between patients receiving recommended doses of Onbrez Breezhaler treatment and those patients who received placebo or treatment with tiotropium. 
Nagu demonstreeriti 605 KOKihaige osalusega 26-nädalases, topeltpimedas, platseeboga kontrollitud III faasi uuringus, puudus kliiniliselt oluline erinevus arütmiate tekke osas 24 tunni jooksul, uuringu alguses ja kuni kolmel korral 26-nädalase raviperioodi jooksul Onbrez Breezhaler'i soovitatud annustega ravi saanud ja platseebot või tiotroopiumravi saanud patsientide vahel.
Treatment comparison compared to placebo showed a ratio of rates of 0.68 (95% CI [ 0.47, 0.98]; p-value 0.036) and 0.74 (95% CI [0.56, 0.96]; pvalue 0.026) for 150 microgram and 300 microgram, respectively. 
Ravimi võrdlus platseeboga näitas 0,68 (95% CI [0,47, 0,98]; pväärtus 0,036) ja 0,74 (95% CI [0,56, 0,96]; p-väärtus 0,026) vastavalt 150 mikrogrammi ja 300 mikrogrammi puhul.
The inhalation of the content of one 300 microgram capsule once a day, using the Onbrez Breezhaler inhaler has been shown to provide additional clinical benefit with regard to breathlessness, particularly for patients with severe COPD. 
Ühe 300-mikrogrammise kapsli sisu inhaleerimisel üks kord päevas Onbrez Breezhaler inhalaatorist on saadud täiendavat kliinilist kasu hingelduse leevendamisel, eriti raske KOKiga patsientidel.
Although indacaterol did not affect general reproductive performance in a rat fertility study, a decrease in the number of pregnant F1 offspring was observed in the peri- and post-developmental rat study at an exposure 14-fold higher than in humans treated with Onbrez Breezhaler. 
Kuigi indakaterool ei mõjutanud üldist reproduktsioonivõimet rottidel läbi viidud fertiilsusuuringutes, täheldati Onbrez Breezhaler'iga ravitud rottidel sünnieelse ja-järgse arengu uuringus F1 põlvkonna rottidel tiinete järeltulijate arvu langust 14 korda kõrgema ekspositsiooniga kui inimestel.
If paradoxical bronchospasm occurs Onbrez Breezhaler should be discontinued immediately and alternative therapy substituted. 
Paradoksaalse bronhospasmi tekkimisel tuleb Onbrez Breezhaler'i kasutamine otsekohe lõpetada ja alustada alternatiivset ravi.
The European Medicines Agency has waived the obligation to submit the results of studies with Onbrez Breezhaler in all subsets of the paediatric population in chronic obstructive pulmonary disease (COPD) (see section 4.2 for information on paediatric use). 
Euroopa Ravimiamet ei kohusta esitama Onbrez Breezhaler'iga läbi viidud uuringute tulemusei laste kõikide alarühmade kohta kroonilise obstruktiivse kopsuhaiguse (KOK) korral (teave lastel kasutamise kohta: vt lõik 4.2).
Do not wash your inhaler with water. 
Ärge peske inhalaatorit veega.
After you have inhaled the medicine: 
Kui olete ravimi sisse hinganud:
Onbrez Breezhaler should not be used in conjunction with other long-acting beta2-adrenergic agonists or medicinal products containing long-acting beta2-adrenergic agonists. 
Onbrez Breezhaler'it ei tohi kasutada koos teiste pikatoimeliste beeta-2-adrenomimeetikumidega või ravimitega, mis sisaldavad pikatoimelisi beeta-2-adrenomimeetikume.
Although no clinically relevant effect on the cardiovascular system is usually seen after the administration of Onbrez Breezhaler at the recommended doses, as with other beta2-adrenergic agonists, indacaterol should be used with caution in patients with cardiovascular disorders (coronary artery disease, acute myocardial infarction, cardiac arrhythmias, hypertension), in patients with convulsive disorders or thyrotoxicosis, and in patients who are unusually responsive to beta2adrenergic agonists. 
Kuigi Onbrez Breezhaler'i soovitatavate annuste manustamise järgselt ei täheldata tavaliselt kliiniliselt olulist toimet kardiovaskulaarsüsteemile, tuleb indakaterooli sarnaselt teiste beeta-2-adrenomimeetikumidega kasutada ettevaatlikult patsientidel, kellel esinevad kardiovaskulaarsed haigused (koronaartõbi, äge müokardiinfarkt, südame rütmihäired, hüpertensioon), krambiseisundid või türeotoksikoos, ning samuti patsientidel, kes on ebatavaliselt tundlikud beeta-2-adrenomimeetikumide suhtes.
Onbrez Breezhaler was shown to reduce lung hyperinflation, resulting in increased inspiratory capacity during exercise and at rest, compared to placebo. 
Onbrez Breezhaler vähendas kopsude hüperinflatsiooni, mille tulemusena suurenes inspiratoorne kapatsiteet vastavalt koormusel ja puhkeolekus võrreldes platseeboga.
The 24-hour bronchodilator effect of Onbrez Breezhaler was maintained from the first dose throughout a one-year treatment period with no evidence of loss in efficacy (tachyphylaxis). 
Onbrez Breezhaler'i 24-tunnine bronhe lõõgastav toime püsis esimesest annusest kuni üheaastase raviperioodi lõpuni, ilma et oleks ilmnenud toime kadumist (tahhüfülaksia).
Onbrez Breezhaler has not been investigated in patients with not well controlled diabetes mellitus. 
Onbrez Breezhaler'i kasutamist ei ole uuritud halvasti kontrollitud diabeediga patsientidel.
At 600 microgram once-daily, the safety profile of Onbrez Breezhaler was overall similar to that of recommended doses. 
600 mikrogrammi üks kord päevas annuse korral oli Onbrez Breezhaler'i ohutusprofiil üldiselt sarnane soovitatud annuste puhul täheldatuga.
Upon initiation of treatment with Onbrez Breezhaler plasma glucose should be monitored more closely in diabetic patients. 
Onbrez Breezhaler'iga ravi alustamise järgselt tuleb diabeetikutel hoolikamalt jälgida plasma glükoosisisaldust.
What Onbrez Breezhaler is and what it is used for What you need to know before you use Onbrez Breezhaler How to use Onbrez Breezhaler Possible side effects 
Mis ravim on Onbrez Breezhaler ja milleks seda kasutatakse Mida on vaja teada enne Onbrez Breezhaler'i kasutamist Kuidas Onbrez Breezhaler'it kasutada Võimalikud kõrvaltoimed
Formoterol twice a day 
Formoteroo l 12 2x päevas
Therefore, long-acting beta2-adrenergic agonists such as Onbrez Breezhaler should be used with caution in patients with known or suspected prolongation of the QT interval or treated with medicinal products affecting the QT interval. 
Seega tuleb pikatoimelisi beeta-2-adrenomimeetikume kasutada ettevaatusega patsientidel, kellel esineb või kahtlustatakse QT-intervalli pikenemist või kes kasutavad QT-intervalli mõjutavaid ravimpreparaate.
In the event of deterioration of COPD during treatment with Onbrez Breezhaler, a reevaluation of the patient and of the COPD treatment regimen should be undertaken. 
Kui ravi ajal Onbrez Breezhaler'iga tekib KOKi süvenemine, tuleb patsiendi seisundit ja KOKi raviskeemi uuesti hinnata.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Onbrez Breezhaler therapy, taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman. 
Rinnaga toitmise katkestamine või ravi katkestamine/jätkamine, tuleb otsustada arvestades imetamise kasu lapsele ja ravi kasu naisele.
Your Onbrez Breezhaler pack: Each Onbrez Breezhaler pack contains: one Onbrez Breezhaler inhaler one or more blisters containing Onbrez Breezhaler capsules to be used in the inhaler. 
Onbrez Breezhaler'i pakend: Igas Onbrez Breezhaler'i pakendis sisaldub: üks Onbrez Breezhaler inhalaator, üks või mitu inhalaatoris kasutatavaid Onbrez Breezhaler kapsleid sisaldavat blistrit.
Renal impairment No dose adjustment is required for patients with renal impairment. 
Neerukahjustus Neerukahjustusega patsientidel ei ole vaja annust muuta.
The capsules must be administered only using the Onbrez Breezhaler inhaler (see section 6.6). 
Kapslite manustamiseks tohib kasutada ainult Onbrez Breezhaler inhalaatorit (vt lõik 6.6).
How to store Onbrez Breezhaler Contents of the pack and other information 
Kuidas Onbrez Breezhaler'it säilitada Pakendi sisu ja muu taeve
Do not take the inhaler apart. 
Ärge võtke inhalaatorit osadeks lahti.
At the recommended doses, the adverse reaction profile of Onbrez Breezhaler in patients with COPD shows clinically insignificant systemic effects of beta2-adrenergic stimulation. 
Soovitatud annuste puhul näitab Onbrez Breezhaler'i kõrvaltoimete profiil KOKihaigetel kliiniliselt ebaolulisi süsteemseid toimeid seoses beeta-2-adrenergilise stimulatsiooniga.
The recommended dose is the inhalation of the content of one 150 microgram capsule once a day, using the Onbrez Breezhaler inhaler. 
Soovitatavaks annuseks on ühe 150-mikrogrammise kapsli sisu inhalatsioon üks kord päevas Onbrez Breezhaler inhalaatorist.
Other medicines and Onbrez Breezhaler 
Muud ravimid ja Onbrez Breezhaler
The Onbrez Breezhaler Phase III clinical development programme involved patients with a clinical diagnosis of moderate to severe COPD. 
Onbrez Breezhaler'i III faasi kliinilises arendusprogrammis osalesid patsiendid, kelle kliiniliseks diagnoosiks oli keskmise raskusega või raske KOK.
How long to continue your treatment with Onbrez Breezhaler Keep using your treatment with Onbrez Breezhaler for as long as your doctor tells you. 
Kui kaua tuleb jätkata ravi Onbrez Breezhaler'iga Jätkake ravi Onbrez Breezhaler'iga senikaua, kui arst soovitab.
Immediate hypersensitivity reactions have been reported after administration of Onbrez Breezhaler. 
On teatatud kohestest ülitundlikkusreaktsioonidest pärast Onbrez Breezhaler'i manustamist.
The Onbrez Breezhaler inhaler provided with each new prescription should be used. 
Kasutada tuleb iga uue retseptiga ette nähtud Onbrez Breezhaler inhalaatorit.
Paediatric population There is no relevant use of Onbrez Breezhaler in the paediatric population (under 18 years). 
Puudub Onbrez Breezhaler'i asjakohane kasutus lastel (vanuses alla 18 aasta).
Onbrez Breezhaler contains the active substance indacaterol which belongs to a group of medicines called bronchodilators. 
Onbrez Breezhaler sisaldab toimeainena indakaterooli, mis kuulub bronhodilataatoriteks ehk bronhilõõgastiteks nimetatud ravimite rühma.
An increase in the daily dose of Onbrez Breezhaler beyond the maximum dose of 300 microgram is not appropriate. 
Onbrez Breezhaler'i ööpäevast annust ei tohi suurendada üle maksimaalse annuse, milleks on 300 mikrogrammi.
Clinically relevant effects on prolongation of the QTc-interval have not been observed in clinical studies of Onbrez Breezhaler at recommended therapeutic doses (see section 5.1). 
Onbrez Breezhaler'i kliinilistes uuringutes ei ole soovitatavate terapeutiliste annuste kasutamisel täheldatud kliiniliselt olulisi toimeid QTc-intervalli pikenemisele (vt lõik 5.1).
What Onbrez Breezhaler contains - Each Onbrez Breezhaler 150 microgram capsule contains 150 microgram indacaterol as indacaterol maleate. 
Mida Onbrez Breezhaler sisaldab - Iga Onbrez Breezhaler 150-mikrogrammine kapsel sisaldab 150 mikrogrammi indakaterooli indakateroolmaleaadina.
Breezhaler capsules with any other inhaler, and do not use Onbrez Breezhaler inhaler to take any other capsule medicine. 
Onbrez Breezhaler kapsleid üheski teises inhalaatoris, samuti ärge kasutage Onbrez Breezhaler inhalaatorit ühegi teise kapslites ravimi manustamiseks.
Onbrez Breezhaler is not indicated for the treatment of acute episodes of bronchospasm, i.e. as rescue therapy. 
Onbrez Breezhaler ei ole näidustatud ägedate bronhospasmi episoodide raviks, st hooravimina.
There are no data available for use of Onbrez Breezhaler in patients with severe hepatic impairment. 
Puuduvad andmed Onbrez Breezhaler'i kasutamise kohta raske maksakahjustusega patsientidel.
During clinical studies, clinically notable changes in blood glucose were generally more frequent by 1-2% on Onbrez Breezhaler at the recommended doses than on placebo. 
Kliinilistes uuringutes esines Onbrez Breezhaler'i soovitatavate annuste kasutamisel veresuhkru taseme kliiniliselt väljendunud muutusi üldiselt sagedamini (1...2% võrra) kui platseebo puhul.
Onbrez Breezhaler 150 microgram capsules have a black product code “IDL 150” printed above a black bar and a black company logo ( ) printed below the black bar. 
Onbrez Breezhaler 150-mikrogrammistele kapslitele on trükitud mustas kirjas toote kood „IDL 150“ musta joone kohale ja firma logo ( ) musta joone alla.
Onbrez Breezhaler 300 microgram capsules have a blue product code “IDL 300” printed above a blue bar and a blue company logo ( ) printed below the blue bar. 
Onbrez Breezhaler 300-mikrogrammistele kapslitele on trükitud sinises kirjas toote kood „IDL 300“ sinise joone kohale ja firma logo ( ) sinise joone alla.
Always keep the Onbrez Breezhaler inhaler and capsules in a dry place. 
Hoidke Onbrez Breezhaler inhalaatorit ja kapsleid alati kuivas kohas.
Onbrez Breezhaler, administered once a day at doses of 150 microgram and 300 microgram, showed clinically meaningful improvements in lung function. 
Onbrez Breezhaler'i manustamine üks kord päevas annustes 150 ja 300 mikrogrammi viis kopsufunktsiooni kliiniliselt olulise paranemiseni.
Onbrez Breezhaler capsules must not be swallowed. 
Onbrez Breezhaler kapsleid ei tohi alla neelata.
Only use the capsules with the inhaler provided in this pack (Onbrez Breezhaler inhaler). 
Kasutage kapsleid ainult koos selles pakendis oleva inhalaatoriga (Onbrez Breezhaler inhalaator).
• Only use the Onbrez Breezhaler inhaler contained in this pack. 
• Kasutage ainult selles pakendis sisalduvat Onbrez Breezhaler inhalaatorit.
What you need to know before you use Onbrez Breezhaler 
Mida on vaja teada enne Onbrez Breezhaler'i kasutamist
Tiotropium once a day 
Tiotroopiu m 18 1x päevas
Stop using the medicine and tell your doctor immediately if you get tightness of the chest, coughing, wheezing or breathlessness immediately after using the medicine. 
Kui teil tekib vahetult pärast ravimi kasutamist rindkere pingsus, köha, vilisev hingamine või hingeldus, lõpetage otsekohe ravimi kasutamine ja teavitage sellest oma arsti.
- Each Onbrez Breezhaler 300 microgram capsule contains 300 microgram indacaterol as indacaterol maleate. 
- Iga Onbrez Breezhaler 300-mikrogrammine kapsel sisaldab 300 mikrogrammi indakaterooli indakateroolmaleaadina.
medicines called beta blockers that are used for high blood pressure or other heart problems (such as propranolol), or for the eye problem called glaucoma (such as timolol). 
Teil võivad suurema tõenäosusega tekkida kõrvaltoimed; beeta-blokaatoriteks nimetatud ravimid, mida kasutatakse kõrgvererõhu või teiste südameprobleemide korral (nt propranolool) või glaukoomiks nimetatud silmahaiguse korral (nt timolool); vere kaaliumisisaldust alandavad ravimid.
Onbrez Breezhaler contains lactose 
Onbrez Breezhaler sisaldab laktoosi
10 capsules + 1 inhaler 30 capsules + 1 inhaler 
10 kapslit + 1 inhalaator 30 kapslit + 1 inhalaator
Show the pack of Onbrez Breezhaler. 
Näidake Onbrez Breezhaler'i pakendit.
The Onbrez Breezhaler inhaler enables you to inhale the medicine contained in a capsule. 
Onbrez Breezhaler inhalaator võimaldab kapslis sisalduvat ravimit sisse hingata.
Tell your doctor immediately if your COPD symptoms (breathlessness, wheezing, cough) do not improve or get worse. 
Kui KOKi sümptomid (hingeldus, vilisev hingamine, köha) ei parane või süvenevad, rääkige sellest otsekohe oma arstile.
Onbrez Breezhaler inhaler 
Onbrez Breezhaler inhalaator
Onbrez Breezhaler is used to make breathing easier for adult patients who have breathing difficulties due to a lung disease called chronic obstructive pulmonary disease (COPD). 
Onbrez Breezhaler'it kasutatakse hingamise kergemaks muutmiseks kroonilisest obstruktiivsest kopsuhaigusest (KOK) tingitud hingamisraskustega täiskasvanutel.
Never wash the Onbrez Breezhaler inhaler with water. 
Ärge kunagi peske Onbrez Breezhaler inhalaatorit veega.
Carton containing 30 capsules and one Onbrez Breezhaler inhaler. 
Karbis on 30 kapslit ja üks Onbrez Breezhaler inhalaator.
What Onbrez Breezhaler is and what it is used for 
Mis ravim on Onbrez Breezhaler ja milleks seda kasutatakse
Onbrez Breezhaler is indicated for maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease (COPD). 
Onbrez Breezhaler on näidustatud bronhe lõõgastavaks säilitusraviks hingamisteede obstruktsiooni korral kroonilise obstruktiivse kopsuhaigusega (KOK) täiskasvanud patsientidel.
Talk to your doctor or pharmacist before using Onbrez Breezhaler if you have asthma (in this case you should not use Onbrez Breezhaler). 
Enne Onbrez Breezhaler'i kasutamist pidage nõu oma arsti või apteekriga: kui teil on astma (sellisel juhul ei tohi Onbrez Breezhaler'it kasutada); kui teil on probleeme südamega; kui teil on epilepsia; kui teil on probleeme kilpnäärmega (türeotoksikoos); kui teil on suhkurtõbi.
Carton containing 10 capsules and one Onbrez Breezhaler inhaler. 
Karbis on 10 kapslit ja üks Onbrez Breezhaler inhalaator.
Only use the Onbrez Breezhaler inhaler contained in this pack. 
Kasutage ainult selles pakendis sisalduvat Onbrez Breezhaler inhalaatorit.
The Onbrez Breezhaler inhaler enables you to inhale the medicine contained in an Onbrez Breezhaler capsule. 
Onbrez Breezhaler inhalaator võimaldab sisse hingata Onbrez Breezhaler kapslis sisalduvat ravimit.
When you start a new pack, use the new Onbrez Breezhaler inhaler that is supplied in the pack. 
Kui alustate uue pakendi kasutamist, kasutage pakendis olevat uut Onbrez Breezhaler inhalaatorit.
You should not use Onbrez Breezhaler unless your doctor tells you so. 
Onbrez Breezhaler'it tohib kasutada ainult juhul, kui arst seda soovitab.
Always use the new Onbrez Breezhaler inhaler that comes with your new pack. 
Kasutage alati uut Onbrez Breezhaler inhalaatorit, mis on uues pakendis.
10 capsules and 1 inhaler. 
10 kapslit ja 1 inhalaator.
Onbrez Breezhaler is a single-dose inhalation device. 
Onbrez Breezhaler on inhalatsiooniseade ühekordse annuse manustamiseks.
During treatment with Onbrez Breezhaler, 
Ravi ajal Onbrez Breezhaler'iga
What Onbrez Breezhaler is used for 
Milleks Onbrez Breezhaler'it kasutatakse
Never place a Onbrez Breezhaler capsule directly into the mouthpiece of the Onbrez Breezhaler inhaler. 
Ärge kunagi pange Onbrez Breezhaler kapslit otse Onbrez Breezhaler inhalaatori huulikusse.
If you forget to inhale a dose, inhale just one dose at the usual time the next day. 
Kui te unustate Onbrez Breezhaler'it kasutada Kui te unustate annuse sisse hingamata, hingake järgmisel päeval tavalisel ajal sisse vaid üks annus.
Indacaterol once a day 
Indakatero ol 300 1x päevas
Each capsule contains indacaterol maleate equivalent to 150 microgram indacaterol. 
Iga kapsel sisaldab indakateroolmaleaati koguses, mis vastab 150 mikrogrammile indakateroolile.
Each inhaler should be disposed of after 30 days of use. 
Pärast 30 päevast kasutamisaega tuleb inhalaator hävitada.
Each capsule contains indacaterol maleate equivalent to 300 microgram indacaterol. 
Iga kapsel sisaldab indakateroolmaleaati koguses, mis vastab 300 mikrogrammile indakateroolile.
• When you start a new pack, only use the new Onbrez Breezhaler inhaler that is supplied in the pack. 
• Kui alustate ravimi kasutamist uuest pakendist, kasutage uut pakendis olevat Onbrez Breezhaler inhalaatorit.
Never take the Onbrez Breezhaler inhaler apart. 
Ärge kunagi võtke Onbrez Breezhaler inhalaatorit osadeks lahti.
Do not store the capsules in the Onbrez Breezhaler inhaler. 
Ärge hoidke kapsleid Onbrez Breezhaler inhalaatoris.
How much Onbrez Breezhaler to use 
Kui palju Onbrez Breezhaler'it kasutada
INSTRUCTIONS FOR USE OF ONBREZ BREEZHALER INHALER 
ONBREZ BREEZHALER INHALAATORI KASUTUSJUHEND
Do not swallow Onbrez Breezhaler capsules. 
Ärge neelake Onbrez Breezhaler kapsleid.
Common 1 Reports of hypersensitivity have been received from post-approval marketing experience in association with the use of Onbrez Breezhaler. 
Turuletulekujärgselt on teatatud Onbrez Breezhaler'i kasutamisega seotud ülitundlikkusest.
Some people may occasionally cough briefly soon after inhaling the medicine. 
Varsti pärast ravimi sissehingamist võib mõnel inimesel tekkida lühiajaline köha.
Lung function 
Kopsufunktsioon
Onbrez Breezhaler 150 microgram inhalation powder, hard capsules Onbrez Breezhaler 300 microgram inhalation powder, hard capsules indacaterol 
Onbrez Breezhaler 150 mikrogrammi inhaleeritav pulber kõvakapslites Onbrez Breezhaler 300 mikrogrammi inhaleeritav pulber kõvakapslites indakaterool (indacaterolum)
How to use Onbrez Breezhaler 
Kuidas Onbrez Breezhaler'it kasutada
Onbrez Breezhaler 300 microgram inhalation powder, hard capsules indacaterol 
Onbrez Breezhaler 300 mikrogrammi inhaleeritav pulber kõvakapslites indacaterolum
53 b 55 c 
53 a b b c b
Onbrez Breezhaler 300 microgram inhalation powder, hard capsules 
Onbrez Breezhaler 300 mikrogrammi inhaleeritav pulber kõvakapslites
Onbrez Breezhaler 150 microgram inhalation powder, hard capsules 
Onbrez Breezhaler 150 mikrogrammi inhaleeritav pulber kõvakapslites
How to store Onbrez Breezhaler 
Kuidas Onbrez Breezhaler'it säilitada
In particular, please tell your doctor if you are using: medicines for breathing problems that are similar to Onbrez Breezhaler (i.e. medicines such as salmeterol and formoterol). 
Onbrez Breezhaler'iga sarnased ravimid (ravimid nagu salmeterool ja formoterool) hingamisprobleemide leevendamiseks.
Onbrez Breezhaler 150 microgram inhalation powder, hard capsules indacaterol 
Onbrez Breezhaler 150 mikrogrammi inhaleeritav pulber kõvakapslites indacaterolum
OUTER CARTON OF UNIT PACK 
ÜKSIKPAKENDI KARP
What Onbrez Breezhaler is 
Mis ravim on Onbrez Breezhaler
Ontruzant trastuzumab 
Ontruzant trastusumaab
What is Ontruzant and what is it used for? 
Mis on Ontruzant ja milleks seda kasutatakse?
What measures are being taken to ensure the safe and effective use of Ontruzant? 
Mis meetmed võetakse, et tagada Ontruzanti ohutu ja efektiivne kasutamine?
The full EPAR for Ontruzant can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Euroopa avaliku hindamisaruande täistekst Ontruzanti kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
This means that Ontruzant is similar to another biological medicine (the ‘reference medicine') that is already authorised in the European Union (EU). 
See tähendab, et Ontruzant sarnaneb bioloogilise ravimiga (võrdlusravimiga), millel juba on Euroopa Liidus müügiluba.
Why is Ontruzant approved? 
Miks Ontruzant heaks kiideti?
The infusion can be associated with allergic reactions, so the patient should be monitored during and after the infusion. 
Infusioon võib tekitada allergilisi reaktsioone, mistõttu tuleb patsienti infusiooni ajal ja järel jälgida.
In addition, a study involving 875 patients with early or locally advanced breast cancer looked at the effectiveness of Ontruzant and Herceptin. 
Uuringus, milles osales 875 varases staadiumis või lokaalselt levinud rinnavähiga patsienti, uuriti Ontruzanti ja Herceptini efektiivsust.
It is not intended to provide practical advice on how to use Ontruzant. 
Hindamisaruandes ei anta Ontruzanti kasutamise praktilisi nõuandeid.